Exosomal CD54 can be used as an effective biomarker for esophageal squamous cell carcinoma and CD54 promotes the proliferation and migration of tumor cells in vitro.

Arbidol is a ATR inhibitor to reduce the phosphorylation and activation of MCM2 at Ser108, and innhibits the cell proliferation of ESCC in vitro and in vivo through the DNA replication and cell cycle pathway.

Genome-wide redistribution of KLF5 binding leads to activation of a cell cycle gene expression programme and proliferation control in oesophageal cancer.

Smoking is a risk factor for a broad range of gastrointestinal diseases independent of alcohol consumption.

Both human and microbe cell-free RNA features in plasma could distinguish tumors of different primary locations.

A supervised methodology for mutational signatures outperforms the current standard unsupervised approach revealing new tissue-dependent mutational signatures among which some for obesity.

Genetic and molecular analysis of TP53 exon-6 truncating mutations reveal that these mutations, contrary to current belief, promote tumorigenesis and point towards strategies for treating cancers driven by these prevalent mutations.

TP63 regulates NRG1 in squamous cell cancers, and targeting of NRG1 induces cancer cell differentiation thereby NRG1 is a potential therapeutic target in squamous cell cancers.